European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"Consolidative therapy for PSMA-avid lesions after 3 cycles of apalutamide plus androgen deprivation in metastatic hormone-sensitive prostate cancer: A prospective phase 2 single-arm trial.","authors":"Jian Pan, Beihe Wang, Bin Zhu, Hualei Gan, Xiaoxin Hu, Xiaohang Liu, Xiaomeng Li, Junlong Wu, Hongkai Wang, Qing Zhang, Chang Liu, Shaoli Song, Xuejun Ma, Dingwei Ye, Yao Zhu","doi":"10.1007/s00259-026-07982-4","DOIUrl":"10.1007/s00259-026-07982-4","url":null,"abstract":"<p><strong>Background: </strong>Metastatic hormone-sensitive prostate cancer (mHSPC) with limited metastatic burden presents a therapeutic challenge, with residual PSMA-avid disease post-androgen receptor pathway inhibitor (ARPI) treatment poorly characterized in prospective studies.</p><p><strong>Patients and methods: </strong>The CHAMPION trial (NCT05717582) was a multicenter, single-arm, phase II study designed to evaluate the efficacy and safety of a response-adapted treatment strategy incorporating consolidative therapy (TCT) for PSMA-avid residual resistant clones following ARPI in newly diagnosed mHSPC patients with ≤ 10 conventional imaging (CI)-defined distant metastases from March 2023 to August 2024. PSMA PET/CT scans were performed at baseline and after three cycles of apalutamide plus castration. Patients with > 10 PSMA-positive distant metastases continued apalutamide therapy, while those with ≤ 10 metastases underwent radical prostatectomy or radiotherapy, with stereotactic body radiotherapy targeting all remaining PSMA-positive lesions, if present. The primary endpoint was the proportion of patients achieving an undetectable PSA level (≤ 0.2 ng/mL) after 6 cycles of apalutamide.</p><p><strong>Results: </strong>A total of 48 patients with a median baseline PSA level of 56.8 ng/mL were enrolled. Baseline CI revealed 1-3 distant metastases in 31 patients (64.6%) and 4-10 in 17 patients (35.4%). Baseline PSMA PET/CT showed 1-3 distant metastases in 17 patients (35.4%), 4-5 in 8 patients (16.7%), and > 5 in 23 patients (47.9%); the most common PSMA-positive sites were bone (47/48, 97.9%), regional lymph nodes (28/48, 58.3%), and distant lymph nodes (15/48, 31.3%). After 3-cycle of apalutamide, two patients with > 10 PSMA-positive metastases continued apalutamide, while the remaining 46 with ≤ 10 metastases received TCT. After six cycles, the overall undetectable PSA rate was 95.8% (46/48; 95% CI: 86.0%-98.8%), a 29.1% increase from the 66.7% (32/48) observed after three cycles. Only two patients (4.2%) experienced grade ≥ 3 rash. Post-treatment, distant lymph node metastases showed the highest response rate at 93.3% (140/150), followed by vertebral column and pelvis bone metastases at 78.5% (255/325), and other bone metastases at 50.0% (58/116), with significant differences between each metastatic site pair (p < 0.0001).</p><p><strong>Conclusions: </strong>This novel treatment paradigm, integrating PSMA PET/CT-guided TCT for residual lesions with intensified systemic therapy, was associated with a high PSA response rate and manageable adverse event profile in newly diagnosed mHSPC patients with ≤ 10 distant metastases.</p><p><strong>Trial registration: </strong>NCT05717582. Registered: 8 February 2023.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"6429-6441"},"PeriodicalIF":7.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148197794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel imaging approach in hyperparathyroidism: [68Ga]Ga-Trivehexin PET/CT.","authors":"Dilara Denizmen Zorba, Serkan Kuyumcu, Duygu Has Simsek, Emine Goknur Isik, Arzu Poyanli, Ayse Kubat Uzum, Fikret Buyukkaya, Semen Onder, Nihat Aksakal, Yalin Iscan, Zeynep Gozde Ozkan, Yasemin Sanli","doi":"10.1007/s00259-026-07965-5","DOIUrl":"10.1007/s00259-026-07965-5","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the diagnostic performance of [68Ga]Ga-Trivehexin PET/CT for localizing hyperfunctioning parathyroid tissue in patients with primary hyperparathyroidism (PHPT) and to compare it with [99mTc]Tc-MIBI scintigraphy with SPECT/CT (MIBI scan).</p><p><strong>Methods: </strong>In this retrospective study, patients with biochemically confirmed PHPT underwent both MIBI scan and [68Ga]Ga-Trivehexin PET/CT. Patient- and lesion-based detection rates were compared between modalities. [68Ga]Ga-Trivehexin PET/CT was acquired at approximately 40 ± 20 min after injection; delayed imaging at 80 ± 20 min was performed in a subset. Dynamic PET imaging was performed in three patients. Quantitative parameters, including SUVmax and lesion-to-background ratios, were recorded. Clinically relevant subgroups, including MEN-1-associated PHPT and persistent disease after surgery, were assessed.</p><p><strong>Results: </strong>A total of 50 parathyroid-related lesions were evaluated in 38 patients. On patient-based analysis, MIBI scan and [68Ga]Ga-Trivehexin PET/CT correctly localized hyperfunctioning parathyroid tissue in 28 of 38 (74%) and 35 of 38 (92%) patients, respectively. On lesion-based analysis, [68Ga]Ga-Trivehexin PET/CT detected 49 of 50 lesions (98%), compared with 29 of 50 lesions (58%) detected by MIBI scan (P < 0.05). [68Ga]Ga-Trivehexin PET/CT demonstrated distinct focal uptake in 18 lesions with negative or equivocal MIBI findings. Dual-time-point imaging showed no significant differences in lesion SUVmax or lesion-to-background ratios between early and delayed scans. Dynamic imaging demonstrated a rapid increase in lesion contrast followed by a plateau, with no consistent improvement beyond approximately 25 min.</p><p><strong>Conclusion: </strong>[68Ga]Ga-Trivehexin PET/CT demonstrated higher detection rates than MIBI scan for localizing hyperfunctioning parathyroid tissue in PHPT, particularly in multiglandular and subcentimetric disease. Early acquisition appears sufficient, with limited added value of delayed imaging.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"6651-6660"},"PeriodicalIF":7.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148149097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PHYTO-PET - Imaging plant physiology on a long-axial field-of-view PET scanner.","authors":"Ian Alberts, Nadine Colpo, Caroline Williams, Michael Woods, Carlos Uribe, Arman Rahmim, François Bénard","doi":"10.1007/s00259-026-07964-6","DOIUrl":"10.1007/s00259-026-07964-6","url":null,"abstract":"<p><strong>Aim: </strong>Non-human imaging using either inanimate phantoms or live animal models is sometimes performed as an alternative to human subjects but involve limitations either in fidelity for the former and ethical considerations for the latter. Plant biology has previously been probed using positron emitting tracers, but the potential for long-axial field-of-view (LAFOV) PET/CT systems with higher sensitivities and longer axial coverage in the imaging of plant biology has not yet been explored.</p><p><strong>Methods: </strong>A selection of both ornamental plants and those of agricultural interest were obtained. A method was developed for the safe instillation of radiopharmaceuticals leading to rapid transport kinetics throughout the plant. [¹⁸F]FDG was obtained from an in-house cyclotron and [⁶⁸Ga]Cl₃ from an onsite ⁶⁸Ge/⁶⁸ Ga generator. The potential for LAFOV PET to probe transport kinetics throughout different vascular compartments was assessed, including for plant models which would not fit within the aFOV of a standard short-axial camera.</p><p><strong>Results: </strong>Several plant models were successfully imaged using both radiopharmaceuticals. Owing to differences in dispersion between [¹⁸F]FDG and [⁶⁸Ga]Cl₃ within the phloem and xylem vascular systems, variation for the in vivo biodistribution was observed between the two radiopharmaceuticals. The transport kinetics were successfully imaged and quantified by means of dynamic imaging and the longer axial coverage lent itself to the imaging of larger plant models, such as Helianthus annuus (Sunflower).</p><p><strong>Conclusion: </strong>LAFOV PET/CT systems are feasible for both static and dynamic imaging of different plant models. In vivo biodistribution and kinetics were successfully demonstrated. The longer axial coverage enabled efficient imaging of multiple plants or plants which would not have fitted within the axial FOV of a short-axial PET/CT system.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"6697-6706"},"PeriodicalIF":7.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148197804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating AD and non-AD [¹⁸F]flortaucipir distribution patterns in a memory clinic cohort.","authors":"Francesco Piva, Cecilia Boccalini, Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow, Giovanni B Frisoni, Mattia Veronese, Valentina Garibotto, Débora Elisa Peretti","doi":"10.1007/s00259-026-07995-z","DOIUrl":"10.1007/s00259-026-07995-z","url":null,"abstract":"<p><strong>Purpose: </strong>Amyloid (A) deposition represents a specific pathological hallmark of Alzheimer's disease (AD). Clinical diagnostic protocols frequently rely on the combined use of amyloid (A)- and tau (T)- positron emission tomography (PET) imaging to distinguish AD from non-amyloid-associated neurodegenerative conditions. Many neurodegenerative disorders are characterized by distinct tauopathies, which result in different [¹⁸F]flortaucipir T-PET topographic patterns. The aim of this study was to investigate, in a memory clinic cohort, whether [¹⁸F]flortaucipir distribution patterns derived from scaled subprofile modelling using principal component analysis (SSM/PCA) could differentiate between A + and A - individuals, potentially eliminating the need for an A-PET.</p><p><strong>Methods: </strong>A total of 81 subjects were included in this study: 40 with AD characterized by both A and T accumulation (A + T +), 13 with suspected non-Alzheimer's pathology (A - T +), and 28 without A and T abnormality (A - T -). SSM/PCA was applied on [¹⁸F]flortaucipir images to identify two disease patterns (DPs), representing amyloid-positive (A + DP) and amyloid-negative (A- DP) accumulation. Each subject's imaging data was then compared to these DPs and the resulting similarity scores were used as inputs for three machine learning models - Support Vector Machine, Random Forest, and Multi-Layer Perceptron - to predict amyloid status. Finally, Spearman correlation analyses were conducted between SSM/PCA-derived scores and plasma biomarkers levels.</p><p><strong>Results: </strong>The two identified disease patterns exhibited distinct PET signatures consistent with current disease knowledge. Their representativeness was further supported by significant correlations with plasma biomarkers in nearly all cases. All machine learning models confirmed the capacity of the A + DP to predict AD pathology, correctly classifying at least 36 out of 40 cases. In contrast, the A - DP showed limited discriminative power for non-AD conditions, as indicated by its higher misclassification rate (best performance: 7 correct out of 13).</p><p><strong>Conclusion: </strong>SSM/PCA applied on [¹⁸F]flortaucipir-PET imaging provide information on both A and T status, supporting its potential use as first and possibly sole examination in the investigation of suspected AD. While for non-AD cases, A-PET scans are still recommended.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"6238-6251"},"PeriodicalIF":7.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13526141/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of ¹⁸F-FDG PET/CT in the prediction of axillary lymph node metastasis in Luminal A breast cancer.","authors":"Kerim Şeker, Hüsnü Çağrı Genç, Tülay Koç, Mukaddes Yılmaz, Zekiye Hasbek","doi":"10.1007/s00259-026-07986-0","DOIUrl":"10.1007/s00259-026-07986-0","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to assess the diagnostic performance of ¹⁸F-FDG PET/CT parameters for the preoperative prediction of axillary lymph node (ALN) metastasis in Luminal A-type breast cancer patients, and to investigate the net clinical benefit of combining visual analysis with quantitative metrics.</p><p><strong>Materials and methods: </strong>We retrospectively evaluated 279 treatment-naive female patients histopathologically diagnosed with Luminal A type breast cancer who underwent ¹⁸F-FDG PET/CT for staging and subsequent ALN sampling between January 2012 and December 2025. Both visual assessment and quantitative parameters-including maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of the primary tumor, as well as axillary SUVmax and the axilla-to-primary SUVmax ratio (SUVr)-were analyzed by two nuclear medicine specialists in consensus. Diagnostic performance was measured using ROC analysis and DeLong's test. The incremental value of the models was evaluated through Net Reclassification Improvement (NRI) and Integrated Discrimination Improvement (IDI), while clinical utility was determined via Decision Curve Analysis (DCA).</p><p><strong>Results: </strong>ALN metastasis was confirmed in 152 (54.5%) patients. All quantitative parameters were significantly higher in the metastatic group (p < 0.001). While expert-based visual analysis showed 84.6% accuracy, axillary SUVmax (AUC: 0.881, 95% CI: 0.841-0.920) significantly outperformed visual assessment (AUC: 0.851, p = 0.031). At a cutoff of 0.93, axillary SUVmax yielded 83.6% sensitivity and 79.5% specificity. The Combined Model, integrating visual and quantitative data, achieved the highest diagnostic power (AUC: 0.889) and was statistically superior to axillary SUVmax alone (p = 0.022). The incorporation of quantitative data correctly reclassified 29% (NRI) of metastatic patients initially reported as false negatives in visual analysis and improved overall discrimination by 41.4% (IDI). DCA revealed that the combined model offered a higher net clinical benefit than standard surgical approaches within a 20-90% risk threshold range.</p><p><strong>Conclusion: </strong>In Luminal A-type breast cancer, objective quantitative 18F-FDG PET/CT parameters and their derived multiparametric models significantly exceed the diagnostic limitations of conventional visual assessment. By providing high net clinical benefit in the surgical decision-making process, the proposed combined model has the potential to serve as a valuable personalized decision support tool for the management of high-risk patients and the de-escalation of invasive surgery in low-risk cohorts.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"6328-6338"},"PeriodicalIF":7.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13526080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148257870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual tracer PET/CT imaging for a patient with lipoadenoma: what Choline missed but Trivehexin revealed.","authors":"Murat Tuncel, Gürsan Kaya, Oğuz Kodaz, Muhammed Furkan Yıldırım, Lütfiye Dilşad Gülkanat","doi":"10.1007/s00259-026-07917-z","DOIUrl":"10.1007/s00259-026-07917-z","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"6137-6138"},"PeriodicalIF":7.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147971564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing subcortical, brainstem and cerebellar metabolic patterns using [18F]FDG PET-CT imaging in dementia with Lewy bodies.","authors":"Daniël S L Loewenstein, Max van Grinsven, Cécile de Pont, Anne I J Arens, Paul L J Dautzenberg, Astrid M van Strien, Osama Sabri, Swen Hesse, Michael Rullmann, Dylan Henssen","doi":"10.1007/s00259-026-07925-z","DOIUrl":"10.1007/s00259-026-07925-z","url":null,"abstract":"<p><strong>Purpose: </strong>Numerous clinical features of Dementia with Lewy Bodies (DLB) are attributed to dysfunction in subcortical anatomy. Despite this, [¹⁸F]FDG PET imaging as a diagnostic tool for DLB largely relies on the metabolic signature of the occipital lobe, precuneus, and posterior cingulate cortex. This study aimed to assess subcortical brain metabolism in patients with DLB using [¹⁸F]FDG PET imaging.</p><p><strong>Methods: </strong>Patients diagnosed with probable DLB were included from both a prospectively maintained regional database (n = 33), and the ADNI database (n = 43). Using statistical parametric mapping (SPM) analysis, metabolic activity was compared with a cohort of subjects exhibiting normal brain metabolism (n = 19). A sub-analysis was conducted with disease progression included as a covariate.</p><p><strong>Results: </strong>Hypermetabolism was observed in various subcortical regions, notably in the dentate nucleus, anterolateral thalamus, and regions of the superior cerebellar peduncle. Increased metabolism was also detected in the mesencephalic tectum, likely representing heightened activity in the superior colliculus. All findings were reproduced in the ADNI cohort and were found to be dependent on the DLB disease stage. Additionally, the well-established cortical hypometabolic signature of DLB pathology was evident, validating our methods and findings.</p><p><strong>Conclusion: </strong>Increased metabolic activity is evident in a variety of brainstem, cerebellar, and subcortical regions in patients with DLB. The dentatorubrothalamic tract, in particular, emerges as a structure of interest that connects these structures and potentially helps in understanding DLB pathophysiology. Correction for disease stage eliminated this pattern, suggesting a driver associated with disease progression.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"6167-6183"},"PeriodicalIF":7.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13526053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148197850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world outcomes of [¹⁷⁷Lu]Lu-PSMA-I&T in [¹⁸F]FDG-positive metastatic castration-resistant prostate cancer: factors related to response and survival.","authors":"Giulia Santo, Gianpaolo di Santo, Ariane Kronthaler, Mohsen Farsad, Lisa Maria Rossetti, Peter Lehmann, Fabian Scherbauer, Francesco Cicone, Irene J Virgolini","doi":"10.1007/s00259-026-07972-6","DOIUrl":"10.1007/s00259-026-07972-6","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Little is known about predictors of response to radionuclide therapy with PSMA-ligands in patients with [&lt;sup&gt;18&lt;/sup&gt;F]FDG-positive metastatic castration-resistant prostate cancer (mCRPC). We assessed the correlation between baseline characteristics, including dual tracer PET parameters, and response to [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-PSMA-I&T in a cohort of patients with [&lt;sup&gt;18&lt;/sup&gt;F]FDG-positive mCRPC. Prognostic factors related to progression-free survival (PFS) and overall survival (OS) were also investigated.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;mCRPC patients who underwent [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-PSMA-11 and [&lt;sup&gt;18&lt;/sup&gt;F]FDG PET/CT prior to [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-PSMA-I&T were retrospectively evaluated. Only [&lt;sup&gt;18&lt;/sup&gt;F]FDG-positive patients were included in the analysis. A semi-automatic segmentation tool was applied to measure the whole-body maximum standardized uptake value (SUV&lt;sub&gt;max&lt;/sub&gt;), mean standardized uptake value (SUV&lt;sub&gt;mean&lt;/sub&gt;), metabolic tumor volume (MTV), and total lesion uptake (TLU) on both PET/CTs. PSA response was defined as ≥ 30% and ≥ 50% decline. Imaging response, assessed two months after the last cycle, was defined according to RECIST 1.1 and/or PSMA PET progression (PPP) criteria. Clinical, biochemical, and imaging-based factors were correlated to response to treatment, PFS, and OS.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Twenty-five [&lt;sup&gt;18&lt;/sup&gt;F]FDG-positive patients who received [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-PSMA-I&T were included. PSA30 and PSA50 responses were achieved in 11/25 (44%) and in 9/25 (36%) patients, respectively. In the univariate analysis [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-PSMA-11 SUV&lt;sub&gt;mean&lt;/sub&gt; (p = 0.022) and [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-PSMA/[&lt;sup&gt;18&lt;/sup&gt;F]FDG SUV&lt;sub&gt;mean&lt;/sub&gt; ratio (p = 0.021) were significantly associated with PSA30 response. [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-PSMA-11 SUV&lt;sub&gt;mean&lt;/sub&gt; was also significant in the multivariate model. ROC analysis indicated an optimal [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-PSMA-11 SUV&lt;sub&gt;mean&lt;/sub&gt; cutoff value of 10.23 (AUC = 0.741), and a best discriminating [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-PSMA/[&lt;sup&gt;18&lt;/sup&gt;F]FDG SUV&lt;sub&gt;mean&lt;/sub&gt; cutoff ratio of 2.08 (AUC = 0.727). In the univariate analysis for radiological PFS (rPFS), high ALP (p = 0.023), [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-PSMA-11 MTV (p = 0.011), [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-PSMA-11 TLU (p = 0.015), and [&lt;sup&gt;18&lt;/sup&gt;F]FDG MTV (p = 0.013) were significantly associated with shorter rPFS. [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-PSMA-11 MTV showed a borderline association with rPFS in the multivariate model (p = 0.061). Hemoglobin levels (p = 0.008), ALP (p = 0.018) and PSA (p = 0.023) values before treatment were associated with OS, as well as [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-PSMA-11 MTV (p = 0.003), [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-PSMA-11 TLU (p = 0.025), and [&lt;sup&gt;18&lt;/sup&gt;F]FDG MTV (p = 0.024). However, no independent predictors of OS were identified in the multivariate analysis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Our preliminary results suggest that a whole-body [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-PSMA-11 SUV&lt;sub","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"6351-6362"},"PeriodicalIF":7.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13526135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148175599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Survival benefit of ⁶⁸Ga-FAPI PET/CT staging for prognostic assessment in gastric and colorectal cancer compared with CE-CT and ¹⁸F-FDG PET/CT: a single-center retrospective study.","authors":"Xiaoxiao Wu, Lingyu Ma, Yan Zhao, Guohong Cai, Jingyi Wang, Ying Guo, Yuanyuan Lu, Yan Pan, Xinyu Du, Yongzhan Nie, Fei Kang, Jing Wang","doi":"10.1007/s00259-026-08026-7","DOIUrl":"10.1007/s00259-026-08026-7","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"6713-6715"},"PeriodicalIF":7.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148344268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Dynamic PSMA-PET for metastasis profiling in prostate cancer: a potential new approach to predict response to therapy.","authors":"Stefano Fanti, Yongkang Shuai, Andrea Farolfi, Irene Brusa, Riccardo Mei","doi":"10.1007/s00259-026-07994-0","DOIUrl":"10.1007/s00259-026-07994-0","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"6710-6712"},"PeriodicalIF":7.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148263751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}